Systems-Pharmacology Dissection of Traditional Chinese Medicine Compound Saffron Formula Reveals Multi-scale Treatment Strategy for Cardiovascular Diseases

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liu, Jianling ^a,b   Mu, Jiexin ^a,b   Zheng, Chunli ^b   Chen, Xuetong ^b   Guo, Zihu ^b   Huang, Chao ^b   Fu, Yingxue ^b   Tian, Guihua ^c   Shang, Hongcai ^c   Wang, Yonghua ^b  

^a NORTHWEST UNIVERSITY   (China)

^b NORTHWEST A F UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; HERBACEOUS AGENT;

ARTIFICIAL NEURAL NETWORK; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; CHEMISTRY; CHINESE MEDICINE; CROCUS; DRUG FORMULATION; HUMAN; METABOLISM;

BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; CROCUS; DRUG COMPOUNDING; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; MODELS, BIOLOGICAL; NEURAL NETWORKS (COMPUTER);

EID: 84955465917     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19809     Document Type: Article

References (64)

1. Lloyd-Jones, D. M. et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113, 791-798 (2006).
2. Hao, P.-P. et al. Traditional Chinese medication for cardiovascular disease. Nat Rev Cardiol 12, 115-122 (2015).
3. Tao, W. et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol 145, 1-10 (2013).
4. Sun, Y. et al. Towards a bioinformatics analysis of anti-Alzheimer's herbal medicines from a target network perspective. Brief Bioinform doi: 10.1093/bib/bbs025 (2012).
5. Xiang, L. et al. The serum metabolomic study of intervention effects of the traditional Chinese medicine Shexiang Baoxin Pill and a multi-component medicine polypill in the treatment of myocardial infarction in rats. Mol BioSyst 8, 2434-2442 (2012).
6. Asdaq, S. M. B. & Inamdar, M. N. Potential of Crocus sativus (saffron) and its constituent, crocin, as hypolipidemic and antioxidant in rats. Appl Biochem Biotech 162, 358-372 (2010).
7. Shiina, Y. et al. Relaxation effects of lavender aromatherapy improve coronary flow velocity reserve in healthy men evaluated by transthoracic Doppler echocardiography. Int J Cardiol 129, 193-197 (2008).
8. Berger, S. I. & Iyengar, R. Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472 (2009).
9. Yan, J. et al. Effect of crocetin on blood pressure restoration and synthesis of inflammatory mediators in heart after hemorrhagic shock in anesthetized rats. Shock 33, 83-87 (2010).
10. Yang, L. et al. Involvement of Ca2+ in the inhibition by crocetin of platelet activity and thrombosis formation. J Agr Food Chem 56, 9429-9433 (2008).
11. Zheng, S. et al. Crocetin attenuates atherosclerosis in hyperlipidemic rabbits through inhibition of LDL oxidation. J Cardiovasc Pharm 47, 70-76 (2006).
12. Wu, Q. et al. Protective effects of muscone on ischemia-reperfusion injury in cardiac myocytes. J Ethnopharmacol 138, 34-39 (2011).
13. Xian, Y.-F. et al. Anti-inflammatory effect of patchouli alcohol isolated from Pogostemonis Herba in LPS-stimulated RAW264. 7 macrophages. Exp Ther Med 2, 545-550 (2011).
14. García-Lafuente, A. et al. Flavonoids as anti-inflammatory agents: Implications in cancer and cardiovascular disease. Inflamm Res 58, 537-552 (2009).
15. Nagao, T., Hase, T. & Tokimitsu, I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity 15, 1473-1483 (2007).
16. Shen, Y.-J. et al. Cardamonin inhibits angiotensin II-induced vascular smooth muscle cell proliferation and migration by downregulating p38 MAPK, Akt, and ERK phosphorylation. J Nat Med 68, 623-629 (2014).
17. Loizou, S. et al. ?-Sitosterol exhibits anti-inflammatory activity in human aortic endothelial cells. Mol Nutr Food Res 54, 551-558 (2010).
18. De Pascual-Teresa, S., Moreno, D. A. & García-Viguera, C. Flavanols and anthocyanins in cardiovascular health: A review of current evidence. Int J Mol Sci 11, 1679-1703 (2010).
19. Willcox, B. J., Curb, J. D. & Rodriguez, B. L. Antioxidants in cardiovascular health and disease: Key lessons from epidemiologic studies. Am J Cardiol 101, S75-S86 (2008).
20. Riccioni, G. et al. Protective effect of lycopene in cardiovascular disease. Eur Rev Med Pharmco 12, 183-190 (2008).
21. Koto, R. et al. Linalyl acetate as a major ingredient of lavender essential oil relaxes the rabbit vascular smooth muscle through dephosphorylation of myosin light chain. J Cardiovasc Pharm 48, 850-856 (2006).
22. Li, Y.-H. et al. The antithrombotic effect of borneol related to its anticoagulant property. Am J Chinese Med 36, 719-727 (2008).
23. Li, Q. et al. Acute effects of walking in forest environments on cardiovascular and metabolic parameters. Eur J Appl Physiol 111, 2845-2853 (2011).
24. Lau, G. T. Y. & Leung, L. K. The dietary flavonoid apigenin blocks phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in breast cell lines. Food Chem Toxicol 48, 3022-3027 (2010).
25. Bektic, J. et al. The flavonoid apigenin inhibits the proliferation of prostatic stromal cells via the MAPK-pathway and cell-cycle arrest in G1/S. Maturitas 55, S37-S46 (2006).
26. Libby, P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83, 456S-460S (2006).
27. Shen, S. H., Wertz, D. L. & Klinman, J. P. Implication for functions of the ectopic adipocyte copper amine oxidase (AOC3) from purified enzyme and cell-based kinetic studies. PloS one. 7(1): P. e29270 (2012).
28. Lee, Y. & Gustafsson, Å. B. Role of apoptosis in cardiovascular disease. Apoptosis 14, 536-548 (2009).
29. Guleria, R. S. et al. Retinoic acid receptor-mediated signaling protects cardiomyocytes from hyperglycemia induced apoptosis: Role of the renin-angiotensin system. J Cell Physiol 226, 1292-1307 (2011).
30. Quyyumi, A. A. Endothelial function in health and disease: New insights into the genesis of cardiovascular disease. Am J Med 105, 32S-39S (1998).
31. Morita, A. et al. Association Between the Calcitonin-Related Peptide ? (CALCA) Gene and Essential Hypertension in Japanese Subjects. Am J Hypertens 20, 527-532 (2007).
32. Watanabe, H. et al. TRP channel and cardiovascular disease. Pharmaco Therapeut 118, 337-351 (2008).
33. Bodineau, L. et al. Orally Active Aminopeptidase A Inhibitors Reduce Blood Pressure A New Strategy for Treating Hypertension. Hypertension 51, 1318-1325 (2008).
34. Friso, S. et al. Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis 199, 323-327 (2008).
35. Zee, R., Hegener, H. & Ridker, P. Carboxypeptidase B2 gene polymorphisms and the risk of venous thromboembolism. J Thromb Haemost 3, 2819-2821 (2005).
36. Kuroda, J. et al. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. P Natl Acad Sci USA 107, 15565-15570 (2010).
37. Miura, T. & Miki, T. GSK-3. BETA, a Therapeutic Target for Cardiomyocyte Protection. Circ J 73, 1184-1192 (2009).
38. Sõber, S., Laan, M. & Annilo, T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem Bioph Res Co 391, 727-732 (2010).
39. Gómez-Hernández, A. et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-? B. Atherosclerosis 187, 139-149 (2006).
40. Padmos, R. C. et al. Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes 57, 2768-2773 (2008).
41. Benjafield, A., Katyk, K. & Morris, B. Association of EDNRA, but not WNK4 or FKBP1B, polymorphisms with essential hypertension. Clin Genet 64, 433-438 (2003).
42. Anderson, M. E. CaMKII and a failing strategy for growth in heart. J Clin Invest 119, 1082-1085 (2009).
43. Hambleton, M. et al. Pharmacological-and gene therapy-based inhibition of protein kinase C?/? enhances cardiac contractility and attenuates heart failure. Circulation 114, 574-582 (2006).
44. Yagmur, E. et al. PTGS1 compound heterozygosity impairs gene expression and platelet aggregation and is associated with severe bleeding complications. Thromb Haemostasis 110, 1083-1085 (2013).
45. Castro-Marrero, J. et al. Genetic risk factors of thrombosis in the antiphospholipid syndrome. Brit J Haematol 147, 289-296 (2009).
46. Cornelissen, I. et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. P Natl Acad Sci USA 107, 18605-18610 (2010).
47. Kim, H.-S. et al. Regulation of angiogenesis by glycogen synthase kinase-3? . J Biol Chem 27, 41888-41896 (2002).
48. Yin, Y.-J. et al. Oncogenic transformation induces tumor angiogenesis: A role for PAR1 activation. FASEB J 17, 163-174 (2003).
49. Huang, C. et al. Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform 15, 710-733 (2013).
50. Zhang, B., Wang, X. & Li, S. An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Luo-Yin. Evid-Based Compl Alt doi: Org/10.1155/2013/456747 (2013).
51. Csermely, P., Agoston, V. & Pongor, S. The efficiency of multi-target drugs: The network approach might help drug design. Trends Pharmacol Sci 26, 178-182 (2005).
52. Kim, F. et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 100, 1589-1596 (2007).
53. Libby, P. Coronary artery injury and the biology of atherosclerosis: Inflammation, thrombosis, and stabilization. Am J Cardiol 86, 3-8 (2000).
54. Ru, J. et al. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J Cheminformatics 6, 13 (2014).
55. Xu, X. et al. A novel chemometric method for the prediction of human oral bioavailability. Int J Mol Sci 13, 6964-6982 (2012).
56. Boulesteix, A.-L. PLS dimension reduction for classification with microarray data. Stat Appl Genet Mol 3, 1-30 (2004).
57. Yamanishi, Y. et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 26, i246-i254 (2010).
58. Wishart, D. S. et al. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34, D668-D672 (2006).
59. Zheng, C. et al. Large-scale Direct Targeting for Drug Repositioning and Discovery. Sci Rep-UK 5 (2015).
60. Consortium, U. The universal protein resource (UniProt). Nucleic Acids Res 36, D190-D195 (2008).
61. Wang, Y. et al. Systems Pharmacology Dissecting Holistic Medicine for Treatment of Complex Diseases: An Example Using Cardiocerebrovascular Diseases Treated by TCM. Evid-Based Compl Alt doi: Org/10.1155/2015/980190 (2015).
62. Dennis, G. Jr et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome biol 4, P3 (2003).
63. Smoot, M. E. et al. Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27, 431-432 (2011).
64. Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504 (2003).